CLINICAL_TRIALS
trial_result
· 2014-04-15
Clinical Trial Update: Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures [Phase 3]
Summary
Phase 3 trial updating on the efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory partial seizures.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bial - Portela C S.A. | Conditions: Partial Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2014-04-15